Market closed

Annovis Bio/$ANVS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Annovis Bio

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Ticker

$ANVS
Sector
Health Care

Trading on

NYSE

Industry

Biotechnology
Headquarters
Malvern, United States

Employees

11
Website
www.annovisbio.com

Annovis Bio Metrics

BasicAdvanced
$66M
-
-$3.97
1.70
-

$66M

1.7

$20.00

$4.21

440K

2.664

2.344

-154.58%

-596.70%

8.97

8.97

-2.29

-18.31%

41.35%

What the Analysts think about Annovis Bio

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Annovis Bio stock.

Annovis Bio Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Annovis Bio Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Annovis Bio News

AllArticlesVideos
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

GlobeNewsWire·1 day ago
Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

GlobeNewsWire·1 month ago
Annovis to Host Year-End Investor Webcast on December 11, 2024

Annovis to Host Year-End Investor Webcast on December 11, 2024

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ANVS

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Annovis Bio stock?

Annovis Bio (ANVS) has a market cap of $66M as of January 15, 2025.

What is the P/E ratio for Annovis Bio stock?

The price to earnings (P/E) ratio for Annovis Bio (ANVS) stock is 0 as of January 15, 2025.

Does Annovis Bio stock pay dividends?

No, Annovis Bio (ANVS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Annovis Bio dividend payment date?

Annovis Bio (ANVS) stock does not pay dividends to its shareholders.

What is the beta indicator for Annovis Bio?

Annovis Bio (ANVS) has a beta rating of 1.7. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.